MDT

96.07

-0.39%↓

A

146.68

-0.14%↓

VEEV

225

-2.38%↓

HQY

84.48

+1.71%↑

PHR.US

16.26

-1.16%↓

MDT

96.07

-0.39%↓

A

146.68

-0.14%↓

VEEV

225

-2.38%↓

HQY

84.48

+1.71%↑

PHR.US

16.26

-1.16%↓

MDT

96.07

-0.39%↓

A

146.68

-0.14%↓

VEEV

225

-2.38%↓

HQY

84.48

+1.71%↑

PHR.US

16.26

-1.16%↓

MDT

96.07

-0.39%↓

A

146.68

-0.14%↓

VEEV

225

-2.38%↓

HQY

84.48

+1.71%↑

PHR.US

16.26

-1.16%↓

MDT

96.07

-0.39%↓

A

146.68

-0.14%↓

VEEV

225

-2.38%↓

HQY

84.48

+1.71%↑

PHR.US

16.26

-1.16%↓

Search

Merck & Co Inc.

Open

SectorHealthcare

109.27 0.77

Overview

Share price change

24h

Current

Min

107.64

Max

108.74

Key metrics

By Trading Economics

Income

1.4B

5.8B

Sales

1.5B

17B

P/E

Sector Avg

14.212

87.826

EPS

2.58

Dividend yield

3.01

Profit margin

33.497

Employees

73,000

EBITDA

1.7B

8.1B

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+9.47% upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

3.01%

2.26%

Next Earnings

3 lut 2026

Next Dividend date

6 kwi 2026

Next Ex Dividend date

16 mar 2026

Market Stats

By TradingEconomics

Market Cap

49B

268B

Previous open

108.5

Previous close

109.27

News Sentiment

By Acuity

34%

66%

103 / 361 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Bearish Evidence

Merck & Co Inc. Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

14 lis 2025, 12:31 UTC

Acquisitions, Mergers, Takeovers

Merck to Buy Cidara Therapeutics in $9.2 Billion Deal -- Update

14 lis 2025, 12:16 UTC

Acquisitions, Mergers, Takeovers

Merck to Buy Cidara Therapeutics in $9.2 Billion Deal

14 lis 2025, 11:20 UTC

Major Market Movers
Acquisitions, Mergers, Takeovers

Cidara Shares Nearly Double Premarket on Report of Takeover by Merck

14 lis 2025, 11:11 UTC

Acquisitions, Mergers, Takeovers

Merck Nears $9.2 Billion Deal for Cidara, FT Reports, Citing Sources

4 lis 2025, 13:03 UTC

Acquisitions, Mergers, Takeovers

Merck Taking Full Control of MK-8690 Development Program

30 paź 2025, 10:45 UTC

Earnings

Merck 3Q Profit Rises on Strong Keytruda Demand

13 paź 2025, 12:19 UTC

Major Market Movers

Bicara Shares Rise Premarket on FDA Breakthrough Designation

11 sie 2025, 12:43 UTC

Major Market Movers

IO Biotech Shares Jump in Premarket on Positive Melanoma Treatment Trial Data

29 lip 2025, 10:45 UTC

Earnings

Merck & Co. to Lay Off Workers, Reduce Real Estate to Invest in New Products

13 sty 2026, 17:38 UTC

Market Talk

Merck CEO Sees $5B Market for Cidara's Flu Antiviral -- Market Talk

13 sty 2026, 17:15 UTC

Market Talk

Merck CEO Sees Eventual Growth After Keytruda Exclusivity Expires -- Market Talk

13 sty 2026, 16:34 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Merck CEO Looking for Strategic Acquisitions -- Market Talk

12 sty 2026, 14:50 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Pharma Sector Can Spend Big on M&A -- Market Talk

9 sty 2026, 19:58 UTC

Acquisitions, Mergers, Takeovers

Merck in Talks to Buy Revolution Medicines for Around $30 Billion -- WSJ

9 sty 2026, 10:54 UTC

Acquisitions, Mergers, Takeovers

Revolution Medicines Stock Soars. Takeover Buzz Grows, Another Suitor Emerges. -- Barrons.com

9 sty 2026, 10:10 UTC

Acquisitions, Mergers, Takeovers

Johnson & Johnson Strikes Deal With White House to Lower Drug Prices -- Barrons.com

7 sty 2026, 11:46 UTC

Acquisitions, Mergers, Takeovers

Merck: Nearly 86% of Cidara Shares Validly Tendered >MRK CDTX

7 sty 2026, 11:45 UTC

Acquisitions, Mergers, Takeovers

Merck To Complete Acquisition Of Cidara Therapeutics >MRK

26 lis 2025, 09:54 UTC

Hot Stocks

Stocks to Watch Wednesday: Dell, HP, Workday -- WSJ

14 lis 2025, 16:30 UTC

Acquisitions, Mergers, Takeovers

Merck Is Paying Up for Flu Biotech as M&A Spree Continues -- Barrons.com

14 lis 2025, 13:19 UTC

Acquisitions, Mergers, Takeovers

This Biotech Stock Is Soaring 100%. Merck Is Buying It. -- Barrons.com

14 lis 2025, 12:22 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Pharma Sector Becoming Bidding Battlefield -- Market Talk

30 paź 2025, 13:49 UTC

Earnings

Merck Stock Falls. Sales of Key Products Missed Estimates. -- Barrons.com

30 paź 2025, 11:32 UTC

Earnings

Bristol Myers Squibb Stock Rises After Solid Earnings. But These Problems Remain. -- Barrons.com

30 paź 2025, 10:51 UTC

Earnings

Merck Stock Falls After Earnings. Keytruda Sales Top $8 Billion for First Time. -- Barrons.com

30 paź 2025, 10:30 UTC

Earnings

Merck 3Q Keytruda Sales Up 10% >MRK

30 paź 2025, 10:30 UTC

Earnings

Merck 3Q Keytruda Sales $8.14B >MRK

7 paź 2025, 10:45 UTC

Acquisitions, Mergers, Takeovers

Merck Completes Acquisition Of Verona Pharma >MRK VRNA

29 lip 2025, 11:13 UTC

Earnings

Merck Stock Falls After Earnings on Revenue Miss and Job Cuts -- Barrons.com

29 lip 2025, 10:45 UTC

Earnings

Merck Stock Falls After Earnings on Revenue Miss and Job Cuts -- Barrons.com

Peer Comparison

Price change

Merck & Co Inc. Forecast

Price Target

By TipRanks

9.47% upside

12 Months Forecast

Average 119.53 USD  9.47%

High 139 USD

Low 95 USD

Based on 16 Wall Street analysts offering 12 month price targets forMerck & Co Inc. - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

16 ratings

11

Buy

5

Hold

0

Sell

Technical Score

By Trading Central

76.03 / 83.28Support & Resistance

Short Term

Bearish Evidence

Intermediate Term

Bearish Evidence

Long Term

Bearish Evidence

Sentiment

By Acuity

103 / 361 Ranking in Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Merck & Co Inc.

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. vIt has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications. It also has licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova. The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.
help-icon Live chat